Trials / Completed
CompletedNCT00290134
A Preliminary Clinical Study to Evaluate Fispemifene in the Treatment of Hypogonadism
Preliminary Efficacy and Safety of Fispemifene in the Treatment of Hypogonadism: A 4 Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing Daily Oral Doses of 100, 200, and 300 mg Fispemifene and Placebo
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 100 (planned)
- Sponsor
- QuatRx Pharmaceuticals Company · Industry
- Sex
- Male
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether one or more fispemifene dose regimens are more effective than placebo in the treatment of hypogonadism in older men.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fispemifene once daily for 4 weeks |
Timeline
- Start date
- 2006-02-01
- Completion
- 2007-10-01
- First posted
- 2006-02-10
- Last updated
- 2008-03-03
Locations
16 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00290134. Inclusion in this directory is not an endorsement.